# SEMPRA (SRE) · Edgar & Edgarette company card

> Sempra (SRE) grew revenue 3.9% in FY2025 to $13.7 billion, equity 28.5% of assets, and dividend per share up 4 years running. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1032208 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/SRE) · [JSON](https://www.pops4.com/boards/company/SRE.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $13.7B |
| Revenue growth, 1 year | 3.9% |
| Revenue growth per year | 1.6% |
| Operating margin | — |
| Net margin | 15.1% |
| Operating cash flow | $4.6B |
| Capital spending | $10.6B |
| Free cash flow | −$6.0B |
| Cash | $29M |
| Long-term debt | $30.9B |
| Total assets | $110.9B |
| Total equity | $31.6B |
| Equity ÷ assets | 28.5% |
| Return on equity | 6.6% |
| Dividend per share | $2.58 |
| Dividend years rising | 4 |

## Readings, computed from those figures

- Piotroski F: 5 of 9 (middling)
- Health Harbor boat: Sound ship · one warning sign · slow and jumpy: growing slower than its size class, with revenue that swings more
- Cash Compass: Fading · slow and jumpy, lagging its peers

## Edgarette's reading

Exposure: revenue $13.7B (FY2025), total debt $30.9B. Experience: revenue up 3.9% on the year, up 1.6% a year over 4 years. Soundness: equity 28.5% of assets, return on equity 6.6%, payout 77.4% of profit, dividend per share up 4 years running. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $11.1B and $16.0B next year (method v4.1: its own 4-year record of growth weighed at 50% against $10B+ filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $9.5B to $18.4B. A statistical range, not company guidance. Against peers (22 filers, $50M+ revenue, its industry group): growth 3.9% against 10.2%.

Range logged 2026-09-26, receipt 0c2ac5b97d8985c7, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 1, latest 2026-07-09 ([filing](https://www.sec.gov/Archives/edgar/data/1032208/000103220826000040/0001032208-26-000040-index.htm))

## Recent filings

- 10-Q · filed 2026-11-05 · [filing](https://www.sec.gov/Archives/edgar/data/1032208/000103220826000054/0001032208-26-000054-index.htm)
- 8-K · filed 2026-11-05 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1032208/000103220826000051/0001032208-26-000051-index.htm)
- 8-K · filed 2026-08-21 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1032208/000119312526361126/0001193125-26-361126-index.htm)
- 8-K · filed 2026-08-18 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1032208/000119312526355501/0001193125-26-355501-index.htm)
- 10-Q · filed 2026-08-06 · [filing](https://www.sec.gov/Archives/edgar/data/1032208/000103220826000045/0001032208-26-000045-index.htm)
- 8-K · filed 2026-08-06 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1032208/000103220826000043/0001032208-26-000043-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001032208.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1032208

## Cite

POPS4, Edgar & Edgarette: SEMPRA (SRE) company card, from the company's own SEC filings, accessed 2026-11-11, https://www.pops4.com/boards/company/SRE. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.